Published: Thu, April 01, 2021

15 million J&J COVID vaccines thrown away after ingredient mix-up

15 million J&J COVID vaccines thrown away after ingredient mix-up

"Johnson & Johnson is providing additional experts in manufacturing, technical operations and quality to be on-site at Emergent to supervise, direct and support all manufacturing of the Johnson & Johnson coronavirus vaccine, " the company said in a statement.

The company said its manufacturing ramp-up "includes test runs and quality checks to ensure manufacturing is validated and the end product meets our high-quality standards". "This batch was never advanced to the filling and finishing stages of our manufacturing process".

The Times report however signaled that issues with quality control could affect future output, with the Food and Drug Administration expected to investigate.

The Johnson & Johnson vaccine could be a game changer in the country's battle against COVID-19, as it only requires a single dose, unlike Pfizer, Moderna and AstraZeneca which each require a second dose to boost immunity.

Johnson & Johnson said that it met a goal of delivering 20 million COVID-19 vaccines by the end of March, and says it is on track to deliver 100 million vaccines by the end of May.

J&J has met its goal to ship 20 million doses to the USA government by the end of March, the company said in its statement.


As of Wednesday, J&J had provided about 6.8 million doses to the USA vaccine effort, according to the Centers for Disease Control and Prevention's online vaccine tracker. He relied on that in moving up his timeline on when the USA would have enough vaccine to cover all adults. The paper reported that federal officials said the mistake was caused by human error.

"Our deliveries of J&J will be beginning at the end of April", she said during a press conference on Tuesday.

Employees at Emergent BioSolutions, a production facility in Baltimore, reportedly mixed-up two vaccine dosages.

"Quality and safety continue to be our top priority", it said.

The FDA told AFP it was "aware of the situation" but declined to comment further.

Like this: